Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 4Myelodysplastic Syndromes 2Myeloproliferative Disorders 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Specimen Handling 6Cytarabine 6fludarabine 5Biopsy 5fludarabine phosphate 4Whole-Body Irradiation 4Tacrolimus 4Granulocyte Colony-Stimulating Factor 4Cyclophosphamide 4venetoclax 3decitabine and cedazuridine drug combination 3Mycophenolic Acid 3Melphalan 3Injections 3Idarubicin 3CPX-351 3Busulfan 3Blood Specimen Collection 3ruxolitinib 2nilotinib 2luspatercept 2ivosidenib 2asciminib 2Thiotepa 2Sirolimus 2Peripheral Blood Stem Cell Transplantation 2Methotrexate 2Liposomes 2Gemtuzumab 2Filgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × olutasidenib × 30 days × Clear all
NCT05564390 2026-06-03

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡